- |||||||||| Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma, Bionovis
Review, Journal: Inclusion of endophytes in hydroponic cultivation of basils enhances hydroxycinnamic acid levels and antioxidant capacity. (Pubmed Central) - Jul 4, 2025 In the antioxidant assay, two of the best endophytes (SB7 and SB9) scavenged hydroxyl radicals by 87.6% and 82.9%, respectively. Additionally, inoculation increased iron-chelating capacity by 40% and fully inhibited lipid oxidation, indicating, overall, the benefits of the inoculation of endophytes during the hydroponic growth of basils.
- |||||||||| Cejemly (sugemalimab) / CStone Pharma, pemetrexed / Generic mfg.
P3 data, Journal, PD(L)-1 Biomarker, IO biomarker: Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial. (Pubmed Central) - Jul 3, 2025 P3 Sugemalimab with chemotherapy showed a superior long-term overall survival benefit compared with placebo with chemotherapy, as a first-line treatment for patients with NSCLC with no known sensitising EGFR, ALK, ROS1, or RET genomic alterations. These results underscore the efficacy of sugemalimab plus platinum-based chemotherapy as a standard first-line treatment option for both squamous and non-squamous metastatic NSCLC while maintaining a manageable safety profile.
- |||||||||| Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma, Bionovis
Journal: Single-cell transcriptomics reveals BMP4-BMPR2 signaling promotes radiation resistance in hematopoietic stem cells following injury. (Pubmed Central) - Jul 2, 2025 We reveal that BMP4 signaling in HSPCs confers IR resistance, and a single administration of BMP4 or SB4 can rescue mice from the IR-induced mortality...In Nrf2 knockout mice, we demonstrate that Nrf2 is a critical downstream functional gene for BMP4-BMPR2 signaling on HSCs to resist IR-induced damage. Collectively, we provide insights into the molecular intricacies underlying HSPC heterogeneity and BM niche after radiation exposure, and we uncover that BMP4-BMPR2 signaling may serve as a promising target for developing innovative and effective intervention strategies to mitigate IR-induced hematopoietic injury.
- |||||||||| Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer, Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
Journal: Expanding the clinical utility of reporter gene assay to infliximab biosimilars. (Pubmed Central) - May 30, 2025 A functional cell-based reporter gene assay was validated for measuring serum concentrations of infliximab biosimilars and neutralizing antibodies. This study supports the bio- equivalency and cross-immunogenicity of parent drug and biosimilars and offers guidance for management of patients switching therapies between parent drug and biosimilars.
- |||||||||| Current trials in China (Plenary room) - May 16, 2025 - Abstract #IGCC2025IGCC_9;
The bispecific antibody AK104, targeting both PD-1 and CTLA-4, has shown promising efficacy and is being investigated for its role in neoadjuvant immunotherapy...Studies such as GEMSTONE-303, RATIONALE-305, and KEYNOTE-859 have demonstrated that PD-1 and PD-L1 inhibitors, including sugemalimab, tislelizumab, and pembrolizumab, improve progression-free survival (PFS), overall survival (OS), and response rates, particularly in patients with high PD-L1 expression...Furthermore, China's innovation in immunotherapy and targeted therapy still relies heavily on international research rather than domestic breakthroughs.Overall, while China has achieved significant advancements in surgical techniques, neoadjuvant therapies, and AI technologies, there remains a need to improve the scale and quality of RCTs, drive domestic drug innovation, advance translational molecular diagnostics, and increase early screening coverage. Moving forward, China should prioritize international collaboration, increase investment in basic research and clinical trials, and accelerate the development of localized innovative therapies to enhance gastric cancer diagnosis, treatment, and patient survival outcomes comprehensively.
- |||||||||| namodenoson (CF102) - Can / Fite
Trial completion date, Trial primary completion date: LIVERATION: Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis (clinicaltrials.gov) - Apr 30, 2025 P3, N=471, Recruiting, Moving forward, China should prioritize international collaboration, increase investment in basic research and clinical trials, and accelerate the development of localized innovative therapies to enhance gastric cancer diagnosis, treatment, and patient survival outcomes comprehensively. Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Feb 2025 --> Feb 2026
- |||||||||| Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma, Bionovis
Clinical, Journal: Topological determinants in protein folding dynamics: a comparative analysis of metamorphic proteins. (Pubmed Central) - Apr 4, 2025 By analyzing folding and unfolding behaviors under varying experimental conditions, our findings suggest that topology dictates folding mechanisms at an early stage. These results demonstrate that folding landscapes are primarily shaped by final native structures rather than sequence composition.
- |||||||||| Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma, Bionovis
Journal: Stabilization of Sb4 Tetrahedra in Paramagnetic Transition Metal Carbonyl Complexes. (Pubmed Central) - Mar 11, 2025 Complex 1 exhibited versatile reactivities toward groups 7-9 metal carbonyls, dioxygen, or [Cu(MeCN)4][BF4] to form selective orbital-controlled Sb4-based products, including transmetalated paramagnetic complexes [Et4N]4[Sb4Cr5Mn(CO)28]Br ([Et4N]4[1-Mn]Br), [Et4N]4[Sb4Cr2Fe6(CO)30] ([Et4N]4[1-Fe]), and [Et4N]2[Sb4Cr4Co4(CO)31] ([Et4N]2[1-Co]), the dioxygen-activated paramagnetic cluster [Et4N]4[O2Sb4Cr6(CO)28] ([Et4N]4[1-O2]), or the spin-quenched complex [Et4N]2[Sb4Cr6(CO)28] ([Et4N]2[2]), respectively. The structural nature, bonding properties, paramagnetism, and semiconductivity of these unprecedented transition metal carbonyl-protected Sb4-based clusters were further realized with DFT calculations.
- |||||||||| piclidenoson (CF101) - Can / Fite
Journal: Local delivery of an adenosine receptor agonist reduces inflammation associated with contact hypersensitivity. (Pubmed Central) - Mar 9, 2025 To our knowledge, this is the first demonstration of therapeutic efficacy of IBMECA in CHS, as well as the first proof-of-principle demonstration of IBMECA application in the context of a local drug delivery system. Ultimately, this delivery system has the potential to be adapted for use in other T-cell mediated inflammatory conditions (e.g., transplant rejection), suggesting broader implications of this study.
- |||||||||| etoricoxib / Generic mfg., Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma, Bionovis
Journal: Formulation and Characterization of Etoricoxib Suppositories for the Management of Hemorrhoids. (Pubmed Central) - Mar 7, 2025 Ultimately, this delivery system has the potential to be adapted for use in other T-cell mediated inflammatory conditions (e.g., transplant rejection), suggesting broader implications of this study. The SB3 gave 91.47
- |||||||||| Uvadex/Therakos Photopheresis (methoxsalen/ECP) / Mallinckrodt
Trial initiation date, Trial suspension, Checkpoint inhibition: EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis (clinicaltrials.gov) - Feb 28, 2025 P2, N=30, Suspended, The SB3 gave 91.47 Initiation date: Jan 2025 --> Dec 2025 | Not yet recruiting --> Suspended
- |||||||||| oxaliplatin / Generic mfg., Cejemly (sugemalimab) / CStone Pharma, capecitabine / Generic mfg.
Clinical, Journal: First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial. (Pubmed Central) - Feb 24, 2025 P3 Sugemalimab plus chemotherapy significantly prolonged overall survival and progression-free survival with a manageable safety profile in previously untreated patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. ClinicalTrials.gov Identifier: NCT03802591.
- |||||||||| namodenoson (CF102) - Can / Fite
Enrollment open: CF102-222PC: Namodenoson Treatment of Advanced Pancreatic Cancer (clinicaltrials.gov) - Jan 31, 2025 P2, N=20, Recruiting, Additionally, Namodenoson's epigenetic modulating activity suggests epigenetic drugs as promising candidates for combination treatment. Not yet recruiting --> Recruiting
- |||||||||| namodenoson (CF102) - Can / Fite
Mediation of the liver protective effect of the anti-cancer drug candidate namodenoson via adiponectin. (Level 1, West Hall; Poster Bd #: D5) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_550; Pharmacists should be following patients who switch to biosimilar closely during the transition period, to monitor for signs of flares/loss of disease control. The anti-cancer effect of namodenoson combined with its protective effects, position it as a unique drug inducing a dual effect in patients with advanced liver cancer.
- |||||||||| Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma, Bionovis
Journal: Structural and electrical characterization of self-assembled Sb4 molecules on metal surfaces. (Pubmed Central) - Dec 2, 2024 Finally, we demonstrated the metallic band structure of Sb4 islands and observed the spatial and energy-dependent contributions of Sb4 molecules to the electronic states. This research enhances the understanding of the synthesis process of antimonene on metal surfaces and provides valuable insights for the industrial production of antimonene.
- |||||||||| Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma, Bionovis
Journal: The influence of geometric nonconformance of the SB4 tension clamps on their strength and elasticity characteristics. (Pubmed Central) - Nov 28, 2024 The properties of the fastening clamps (in their nominal shape) were compared (described in the PKP Polskie Linie Kolejowe S.A. documentation) with the fastening clamps of the actual shape. In the investigation, the authors have confirmed the negative influence of the non-conformance of the shape of the actual fastening clamps with the nominal ones.
- |||||||||| Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma, Bionovis
Journal: Synthesis and evaluation of vanillin Schiff bases as potential antimicrobial agents against ESBL-producing bacteria: towards novel interventions in antimicrobial stewardship. (Pubmed Central) - Nov 19, 2024 The Schiff bases demonstrated notable antibacterial activities, with SB-1, SB-2, SB-4, and SB-5 exhibiting zones of inhibition up to 16.0, 16.5, 16.6, and 15.5 mm against ESBL E. coli, respectively...In cytotoxicity assays, the compounds exhibited IC values against red blood cells (RBCs) greater than 200 ?g/mL and ranging from 45.7 to 50.5 ?g/mL for the brine shrimp assay. While demonstrating potent antibacterial properties, the toxicity towards human RBCs suggests that further toxicity evaluations and structural modifications are essential for developing safer therapeutic agents based on vanillin Schiff bases.
- |||||||||| namodenoson (CF102) - Can / Fite, CGS 21680 / Novartis
Journal: The different effects of four adenosine receptors in liver fibrosis. (Pubmed Central) - Sep 20, 2024 Additionally, 5'-N-ethyl-carboxamidoadenosine (NECA), a metabolically stable adenosine analog, alleviated liver fibrosis and inhibited LX2 cell activity, proliferation, and migration. This study demonstrated the different roles of A1R/A2AR/A2BR/A3R during liver fibrosis development via regulating the HSC activity and proliferation.
- |||||||||| Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer, Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
Observational data, Retrospective data, Journal, Real-world evidence, Real-world: Real-world experience with biosimilar infliximab-adba and infliximab-dyyb among infliximab-na (Pubmed Central) - Sep 20, 2024 IFX utilization and laboratory patterns were clinically similar among the IFX biosimilars and RP groups, suggesting that providers did not modify their practice with biosimilars. Statistically significant differences in IFX utilization patterns are explained by formulary dynamics when the VANF product switched from IFX-dyyb to IFX-abda.
- |||||||||| namodenoson (CF102) - Can / Fite
Journal: Neuroprotective compounds alter the expression of genes coding for proteins related to mitochondrial function in activated microglia. (Pubmed Central) - Sep 11, 2024 In this research, we analyzed by RNAseq the gene expression in activated microglia treated with an adenosine A2A receptor antagonist, SCH 582561, and/or an A3 receptor agonist, 2-Cl-IB-MECA, since these receptors are deeply related to neurodegeneration and inflammation...Additionally, we evaluated the oxygen consumption rate (OCR) of mitochondria in microglia treated with LPS and IFN-?, both alone and in combination with adenosinergic compounds. The data showed an improvement in mitochondrial function with the antagonist of the adenosine A2A receptor, compared to the effects of pro-inflammatory stimulus, confirming a functional effect consistent with the RNAseq data.
- |||||||||| namodenoson (CF102) - Can / Fite
Trial initiation date: CF102-222PC: Namodenoson Treatment of Advanced Pancreatic Cancer (clinicaltrials.gov) - Aug 21, 2024 P2, N=20, Not yet recruiting, In addition, we demonstrated the previously uncharacterized allosteric signaling-enhancing effect of LUF6000 in cells endogenously expressing the hA3AR. Initiation date: Jul 2024 --> Dec 2024
- |||||||||| namodenoson (CF102) - Can / Fite
Journal: Lipid Trolling to Optimize A3 Adenosine Receptor-Positive Allosteric Modulators (PAMs). (Pubmed Central) - Jul 26, 2024 The putative mechanism involves a flexible, terminally cationic chain penetrating the lipid environment for stable electrostatic anchoring to cytosolic phospholipid head groups, suggesting "lipid trolling", supported by molecular dynamic simulation of the active-state model. Thus, we have improved A3AR PAM activity through rational design based on an extrahelical, lipidic binding site.
- |||||||||| Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo, Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma, Bionovis
PK/PD data, Journal: Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis. (Pubmed Central) - Jun 27, 2024 A simulation of dosing the etanercept biosimilar at a lower rate of every 10 days reached steady-state concentrations earlier than the usual dosing rate of every 7 days. Simulations of altered dosing intervals could form the basis for future personalised dosing studies, potentially saving costs whilst increasing efficacy.
- |||||||||| namodenoson (CF102) - Can / Fite, piclidenoson (CF101) - Can / Fite
Review, Journal: Adenosine A3 Receptor: From Molecular Signaling to Therapeutic Strategies for Heart Diseases. (Pubmed Central) - Jun 19, 2024 Several A3AR-specific agonists, such as piclidenoson and namodenoson, exert cardioprotective impacts during ischemia in the diverse animal models of heart disease. Thus, modulating A3ARs serves as a potential therapeutic approach, fueling considerable interest in developing compounds that target A3ARs as potential treatments for heart diseases.
- |||||||||| namodenoson (CF102) - Can / Fite
Journal: Gene regulation in activated microglia by adenosine A receptor agonists: a transcriptomics study. (Pubmed Central) - Jun 18, 2024 Analysis of known and predicted protein-protein interactions showed that Smad3 and Sp1 are transcription factors whose genes are regulated by AR activation. Under the conditions of cell activation and agonist treatment regimen, 2-Cl-IB-MECA did not lead to any tendency to favor the expression of genes related to neuroprotective microglia (M2).
|